カテゴリ： GlobalData, イスラエル, 企業調査

Therapix Biosciences Ltd (TRPX)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Therapix Biosciences Ltd (TRPX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9817
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：65
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イスラエル
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Therapix Biosciences Ltd (Therapix), formerly Nasvax Ltd is a clinical stage biopharmaceutical company that focuses on the development of cannabinoid based pharmaceuticals for the treatment of central nervous system disorders. Therapix’s major product candidates include THX-110, for the treatment of tourette syndrome, obstructive sleep apnea and chronic pain; THX-130, for the treatment of mild cognitive impairment and traumatic brain injury; THX-150, for the treatment of infectious diseases; and THX-160, for the treatment of treat pain. The company conducts its clinical programs in collaboration with various pharma companies and institutions. Therapix Biosciences is headquartered in Tel Aviv, Israel.

Therapix Biosciences Ltd (TRPX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Therapix Biosciences Enters into Agreement with Dalhousie University 12
CURE Pharma Enters into Agreement with Therapix Biosciences 13
Therapix Biosciences Enters into Agreement with Weizmann Institute and Tel Aviv Sourasky 14
Therapix Biosciences Enters into Agreement with Assuta Medical Center 15
Therapix Biosciences Enters into Agreement with Catalent 16
CURE Pharmaceutical and Therapix Biosciences to Enter into Research Agreement with Assuta Medical Centers 17
Therapix Biosciences Plans to Form Joint Venture in China 18
Acebright To Enter Into Co-Development Agreement With NasVax 19
Licensing Agreements 20
Therapix Biosciences Enters into Licensing Agreement with Belvit Pharma 20
Therapix Biosciences to Enter into Licensing Agreement with Yissum Research Development Company 21
Therapix Biosciences to Enter into Licensing Agreement with Swiss Pharma Company 22
Therapix Biosciences Enters into Licensing Agreement with Ramot at Tel Aviv University 23
Therapix Biosciences Enters into Licensing Agreement with Dekel Pharma 24
Therapix Biosciences Enters into Licensing Agreement with Nanjing BioSciKin for Anti-CD3 25
Equity Offering 26
Therapix Biosciences Completes Underwriters Exercise of Over-Allotment of Public Offering of ADSs for USD13.8 Million 26
Therapix Biosciences Raises USD1 Million in Private Placement of Shares 28
Therapix Biosciences Raises USD0.8 Million in Private Placement of Shares 29
Therapix Biosciences Raises USD0.6 Million in Private Placement of Shares 30
Therapix Biosciences Raises USD0.1 Million in Private Placement of Shares 31
Therapix Biosciences Raises USD0.2 Million in Private Placement of Shares 32
Therapix Biosciences Raises USD1 Million in Public Offering of Shares 33
Asset Transactions 34
CURE Pharma Plans to Acquire Assets from Therapix Biosciences 34
Acquisition 35
FSD Pharma to Acquire Therapix Biosciences 35
Therapix Biosciences to Acquire Dekel Pharma 37
Therapix Biosciences Acquires 48.21% Stake in Lara Pharm 38
Acebright To Acquire 10% Stake In NasVax For US$1 Million 39
Therapix Biosciences Ltd – Key Competitors 40
Therapix Biosciences Ltd – Key Employees 41
Therapix Biosciences Ltd – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
Aug 20, 2018: Therapix Biosciences reports second quarter 2018 financial results and provides business update 43
May 31, 2018: Therapix Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update 45
Nov 09, 2017: Therapix Biosciences Reports Third Quarter 2017 Financial Results and Provides Business Update 47
Aug 10, 2017: Therapix Biosciences Reports Second Quarter 2017 Financial Results and Provides Business Update 48
Corporate Communications 49
Jun 27, 2018: Therapix Biosciences Updates Regarding TASE Delisting 49
May 09, 2018: Dual-Listed Therapix to Voluntarily Delist from Tel Aviv Stock Exchange 50
Nov 02, 2017: Therapix Biosciences’ Board Chairman, Ascher Shmulewitz, Appointed as Interim Chief Executive Officer 51
May 24, 2017: Therapix Biosciences Announces CEO Change 52
May 03, 2017: Therapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer 53
Product Approvals 54
Feb 07, 2018: Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected 54
Clinical Trials 55
Jun 11, 2018: Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette Syndrome 55
Jun 05, 2018: Therapix Biosciences Announces Enrollment of the First Patient for Clinical Trial at Assuta Medical Center for Treating Obstructive Sleep Apnea Using Cannabinoid-based Drug 56
Apr 09, 2018: Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program 57
Mar 20, 2018: Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain 58
Dec 04, 2017: Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program 59
Sep 27, 2017: Therapixs First-in-Class Therapy Demonstrates Reversal of Age-Related Cognitive Impairment in Pre-Clinical Study 60
May 08, 2017: Therapix Biosciences and the Hannover Medical School Enter into an Investigator-initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette Syndrome 61
Jan 04, 2017: Therapix Biosciences Announces Enrollment of the First Patient for Clinical Trial at Yale University for Treating Tourette’s Syndrome Using Cannabinoid-based Drug 62
Other Significant Developments 63
May 15, 2018: Therapix Biosciences Issues CEO’s Letter to Shareholders 63
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65

List of Tables
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Therapix Biosciences Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Therapix Biosciences Enters into Agreement with Dalhousie University 12
CURE Pharma Enters into Agreement with Therapix Biosciences 13
Therapix Biosciences Enters into Agreement with Weizmann Institute and Tel Aviv Sourasky 14
Therapix Biosciences Enters into Agreement with Assuta Medical Center 15
Therapix Biosciences Enters into Agreement with Catalent 16
CURE Pharmaceutical and Therapix Biosciences to Enter into Research Agreement with Assuta Medical Centers 17
Therapix Biosciences Plans to Form Joint Venture in China 18
Acebright To Enter Into Co-Development Agreement With NasVax 19
Therapix Biosciences Enters into Licensing Agreement with Belvit Pharma 20
Therapix Biosciences to Enter into Licensing Agreement with Yissum Research Development Company 21
Therapix Biosciences to Enter into Licensing Agreement with Swiss Pharma Company 22
Therapix Biosciences Enters into Licensing Agreement with Ramot at Tel Aviv University 23
Therapix Biosciences Enters into Licensing Agreement with Dekel Pharma 24
Therapix Biosciences Enters into Licensing Agreement with Nanjing BioSciKin for Anti-CD3 25
Therapix Biosciences Completes Underwriters Exercise of Over-Allotment of Public Offering of ADSs for USD13.8 Million 26
Therapix Biosciences Raises USD1 Million in Private Placement of Shares 28
Therapix Biosciences Raises USD0.8 Million in Private Placement of Shares 29
Therapix Biosciences Raises USD0.6 Million in Private Placement of Shares 30
Therapix Biosciences Raises USD0.1 Million in Private Placement of Shares 31
Therapix Biosciences Raises USD0.2 Million in Private Placement of Shares 32
Therapix Biosciences Raises USD1 Million in Public Offering of Shares 33
CURE Pharma Plans to Acquire Assets from Therapix Biosciences 34
FSD Pharma to Acquire Therapix Biosciences 35
Therapix Biosciences to Acquire Dekel Pharma 37
Therapix Biosciences Acquires 48.21% Stake in Lara Pharm 38
Acebright To Acquire 10% Stake In NasVax For US$1 Million 39
Therapix Biosciences Ltd, Key Competitors 40
Therapix Biosciences Ltd, Key Employees 41
Therapix Biosciences Ltd, Subsidiaries 42

List of Figures
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Therapix Biosciences Ltd (TRPX)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Fibra Uno Administracion, S. A. De C. V.
    Fibra Uno Administracion, S. A. De C. V. - Strategy, SWOT and Corporate Finance Report Summary Fibra Uno Administracion, S. A. De C. V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Canadian Zeolite Corp.：企業の戦略・SWOT・財務情報
    Canadian Zeolite Corp. - Strategy, SWOT and Corporate Finance Report Summary Canadian Zeolite Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • New Brunswick Power Corporation：企業の戦略的SWOT分析
    New Brunswick Power Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Herstal SA：企業の戦略・SWOT・財務情報
    Herstal SA - Strategy, SWOT and Corporate Finance Report Summary Herstal SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • The Hut Group Ltd：企業のM&A・事業提携・投資動向
    The Hut Group Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Hut Group Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Pharmerica Corp：企業の戦略的SWOT分析
    Pharmerica Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Teachers Insurance and Annuity Association of America (TIAA)：企業の戦略・SWOT・財務情報
    Teachers Insurance and Annuity Association of America (TIAA) - Strategy, SWOT and Corporate Finance Report Summary Teachers Insurance and Annuity Association of America (TIAA) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers …
  • Aju Pharm Co Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Aju Pharm Co Ltd (Aju Pharm) is a pharma and medical device company. The company operates in the business such as pharmaceutical, CMO, medical device, global business and consumer health business. Its pharmaceutical business provides drugs for hypertension, antibiotics, and anti-inflammatory …
  • Ingosstrakh Joint-Stock Insurance Company Ltd.：企業の戦略・SWOT・財務分析
    Ingosstrakh Joint-Stock Insurance Company Ltd. - Strategy, SWOT and Corporate Finance Report Summary Ingosstrakh Joint-Stock Insurance Company Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • CITIC Telecom International Holdings Ltd (1883)：企業の財務・戦略的SWOT分析
    CITIC Telecom International Holdings Ltd (1883) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • PharmaCyte Biotech Inc (PMCB)：製薬・医療：M&Aディール及び事業提携情報
    Summary PharmaCyte Biotech Inc (PharmaCyte), formerly Nuvilex Inc, is a clinical stage biotechnology company that develops and commercializes treatments for cancer and diabetes. The company offers technology is used for the treatment of advanced and inoperable pancreatic cancer and diabetes. It deve …
  • Symrise AG (SY1)：企業の財務・戦略的SWOT分析
    Symrise AG (SY1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Asda Stores Ltd：企業の戦略・SWOT・財務情報
    Asda Stores Ltd - Strategy, SWOT and Corporate Finance Report Summary Asda Stores Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Siemens Ltd (SIEMENS)：企業の財務・戦略的SWOT分析
    Siemens Ltd (SIEMENS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Laboratorios Farmaceuticos Rovi SA (ROVI)-製薬・医療分野：企業M&A・提携分析
    Summary Laboratorios Farmaceuticos ROVI SA (ROVI) is a drug company that develops and manufactures diagnostic, prescription and over the counter medicinal products. The company's over the counter products include antiperspirant lotions, food supplements, oral gels, cold and hot bags to relieve pains …
  • MEG Energy Corp (MEG)：企業の財務・戦略的SWOT分析
    MEG Energy Corp (MEG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • The Interpublic Group of Companies, Inc.：企業の戦略・SWOT・財務情報
    The Interpublic Group of Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Interpublic Group of Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Grid2020, Inc.：電力：M&Aディール及び事業提携情報
    Summary Grid2020, Inc. (Grid2020) is a provider of smart grid solutions. The company offers an integrated distribution transformer monitoring solutions under the brand Optanode. The Optanode product family consists of sensors and smart analytics software and provides information about the distributi …
  • EDF Renewables SA：企業の戦略的SWOT分析
    EDF Renewables SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Taiwan Cogeneration Corp (8926)：企業の財務・戦略的SWOT分析
    Summary Taiwan Cogeneration Corp (Taiwan Cogeneration) is a power company that offers power and electrical energy generation and cogeneration services. The corporation provides services such as construction, investment, operation, and management of power and energy generation cogeneration plants in …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆